The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force
Abstract
BACKGROUND: Prostate cancer is the most common nonskin cancer in men in the United States, and prostate cancer screening has increased in recent years. In 2002, the U.S. Preventive Services Task Force concluded that evidence was insufficient to recommend for or against screening for prostate cancer with prostate-specific antigen (PSA) testing. PURPOSE: To examine new evidence on benefits and harms of screening asymptomatic men for prostate cancer with PSA. DATA SOURCES: English-language articles identified in PubMed and the Cochrane Library (search dates, January 2002 to July 2007), reference lists of retrieved articles, and expert suggestions. STUDY SELECTION: Randomized, controlled trials and meta-analyses of PSA screening and cross-sectional and cohort studies of screening harms and of the natural history of screening-detected cancer were selected to answer the following questions: Does screening for prostate cancer with PSA, as a single-threshold test or as a function of multiple tests over time, decrease morbidity or mortality? What are the magnitude and nature of harms associated with prostate cancer screening, other than overtreatment? What is the natural history of PSA-detected, nonpalpable, localized prostate cancer? DATA EXTRACTION: Studies were reviewed, abstracted, and rated for quality by using predefined U.S. Preventive Services Task Force criteria. DATA SYNTHESIS: No good-quality randomized, controlled trials of screening for prostate cancer have been completed. In 1 cross-sectional and 2 prospective cohort studies of fair to good quality, false-positive PSA screening results caused psychological adverse effects for up to 1 year after the test. The natural history of PSA-detected prostate cancer is poorly understood. LIMITATIONS: Few eligible studies were identified. Long-term adverse effects of false-positive PSA screening test results are unknown. CONCLUSION: Prostate-specific antigen screening is associated with psychological harms, and its potential benefits remain uncertain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Current methods of the U.S. Preventive Services Task Force
Harris, R. P., Helfand, M., Woolf, S. H., Lohr, K. N., Mulrow, C. D., Teutsch, S. M., & Atkins, D. (2001) · American Journal of Preventive Medicine · doi:10.1016/s0749-3797(01)00261-6 · Cited by 1,731
20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen, P. C. (2005) · JAMA · doi:10.1001/jama.293.17.2095 · Cited by 1,187
Catalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., et al. (1998) · JAMA · doi:10.1001/jama.279.19.1542 · Cited by 1,162
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004720.pub3 · Cited by 1,150
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
Thompson, I., Thrasher, J. B., Aus, G., Burnett, A. L., Canby-Hagino, E. D., Cookson, M. S., D’Amico, A. V., Dmochowski, R. R., Eton, D. T., Forman, J. D., et al. (2007) · Journal of Urology · doi:10.1016/j.juro.2007.03.003 · Cited by 1,113
Radical Prostatectomy versus Watchful Waiting in Early Prostate Cancer
Bill-Axelson, A., Holmberg, L., Ruutu, M., Häggman, M., Andersson, S.-O., Bratell, S., Spångberg, A., Busch, C., Nordling, S., Garmo, H., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043739 · Cited by 1,111
Natural History of Early, Localized Prostate Cancer
Johansson, J.-E. (2004) · JAMA · doi:10.1001/jama.291.22.2713 · Cited by 703
Wilt, T. J., MacDonald, R., Rutks, I., Shamliyan, T. A., Taylor, B. C., & Kane, R. L. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-6-200803180-00209 · Cited by 597
Gohagan, J. K., Prorok, P. C., Hayes, R. B., & Kramer, B.-S. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00097-0 · Cited by 544
Cited by
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Ilic, D., Neuberger, M. M., Djulbegovic, M., & Dahm, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004720.pub3 · Cited by 1,150
Henry, N. L., & Hayes, D. F. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.01.010 · Cited by 849
Ilic, D., Djulbegovic, M., Jung, J. H., Hwang, E. C., Zhou, Q., Cleves, A., Agoritsas, T., & Dahm, P. (2018) · BMJ · doi:10.1136/bmj.k3519 · Cited by 641
Metadata
- Authors
- Lin, K., Lipsitz, R., Miller, T., & Janakiraman, S.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2008-08-05
- Volume
- 149
- Issue
- 3
- Pages
- 192-199
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2138760768
- Cited by
- 310
- References
- 24
- FWCI
- 31.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force. https://app.cochat.ai/papers/10.7326/0003-4819-149-3-200808050-00009
- The paper
- Lin, K., Lipsitz, R., Miller, T., & Janakiraman, S. (2008). Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer: An Evidence Update for the U.S. Preventive Services Task Force. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-149-3-200808050-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.